New Agent Approved for PSMA PET Scanning in Prostate Cancer New Agent Approved for PSMA PET Scanning in Prostate Cancer

The injectable radioactive diagnostic agent, piflufolastatF18 (PYLARIFY), is the first to be commercially available for use in positron-emission tomography (PET) imaging for men with prostate cancer.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news